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Abstract
Background
The strong male predominance in oesophageal adenocarcinoma (OAC) and Barrett’s
oesophagus (BO) continues to puzzle. Hormonal influence, e.g. oestrogen or oxytocin,
might contribute.
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Methods
This genetic-epidemiological study pooled 14 studies from three continents, Australia,
Europe, and North America. Polymorphisms in 3 key genes coding for the oestrogen path-
way (receptor alpha (ESR1), receptor beta (ESR2), and aromatase (CYP19A1)), and 3 key
genes of the oxytocin pathway (the oxytocin receptor (OXTR), oxytocin protein (OXT), and
cyclic ADP ribose hydrolase glycoprotein (CD38)), were analysed using a gene-based
approach, versatile gene-based test association study (VEGAS).
Results
Among 1508 OAC patients, 2383 BO patients, and 2170 controls, genetic variants within
ESR1 were associated with BO in males (p = 0.0058) and an increased risk of OAC and BO
combined in males (p = 0.0023). Genetic variants withinOXTR were associated with an
increased risk of BO in both sexes combined (p = 0.0035) and in males (p = 0.0012). We fol-
lowed up these suggestive findings in a further smaller data set, but found no replication.
There were no significant associations between the other 4 genes studied and risk of OAC,
BO, separately on in combination, in males and females combined or in males only.
Conclusion
Genetic variants in the oestrogen receptor alpha and the oxytocin receptor may be associated
with an increased risk of BO or OAC, but replication in other large samples are needed.
Introduction
Oesophageal adenocarcinoma (OAC) and its premalignant condition Barrett’s oesophagus
(BO) have become increasingly common in the West during the last few decades.[1, 2] The up
to 9:1 male-to-female ratio in OAC remains virtually unexplained.[1, 3]
Oestrogen hypothesis
It has been hypothesised that the female sex hormone oestrogen may counteract the develop-
ment of OAC, a hypothesis supported by a 20 year delay in the onset of this cancer in women
compared to men,[4] and a particularly high male-to-female ratio during women’s reproduc-
tive years, compared to older ages.[5] A possible mechanism of oestrogen on OAC cells
remains to be determined, but the presence of oestrogen receptors has repeatedly been shown
in OAC,[6, 7] and a recent experimental study found that OAC and BO cells respond to treat-
ment with selective oestrogen receptor ligands by decreased cell growth and apoptosis.[8] The
hypothesis of oestrogen protection has, however, not been unequivocally supported in human
studies on pharmacologically exposed individuals or on phenotypes reflecting presumed natu-
ral variation in oestrogen levels.[7] The low incidence of OAC in women and the uncertainty
about the validity of assumptions concerning oestrogen exposure have been of major concern
in previous studies.[3] In the absence of methods for assessment of the integrated steroid expo-
sure given the diurnal and age-dependent within-person variation, assessment of genetic vari-
ants may be an alternative measure to assess oestrogen exposure.[9, 10] To the best of our
knowledge, no previous study has addressed variants in genes known to regulate oestrogen lev-
els in relation to risk of OAC or BO.
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Oxytocin hypothesis
As an increased duration of breastfeeding among women is associated with a substantially
decreased risk of OAC,[11, 12] oxytocin is another conceivable mediator of the gender differ-
ence. Oxytocin levels are much higher in women than in men, and the hormone is richly
released during breastfeeding.[13] Moreover, oxytocin receptors have been identified in the
human gastrointestinal tract.[14] In addition, living without a partner is linked with an
increased risk of OAC,[15] and oxytocin release is stimulated by physical contacts and interac-
tions between people.[13] Higher oxytocin levels have also been shown to correlate with faster
wound healing and less inflammation.[16] A plausible biological mechanism for any protective
effect against OAC or BO is that the smooth muscle-contracting oxytocin[13] might raise the
lower oesophageal sphincter pressure and counteract gastroesophageal reflux, the strongest
known risk factor for OAC and BO.[17–19] We therefore hypothesised that high oxytocin
activity might decrease the risk of OAC and BO. Oxytocin has a short half-life in serum, mak-
ing serum level testing too unstable for research purposes, but polymorphisms in genes coding
for oxytocin and its receptor might provide a marker of low oxytocin activity according to stud-
ies of behaviour and health in humans.[20–22]
To test the oestrogen and oxytocin hypotheses, we studied associations between single
nucleotide polymorphisms (SNPs) in key genes coding for the oestrogen and oxytocin path-
ways in relation to the risks of OAC and BO.
Materials and Methods
Study design
Each study participant provided written informed consent to take part in the research, and the
study was approved by the Fred Hutchinson Cancer Research Center Institutional Review
Board in Seattle, WA. USA (number 7030, date 8/8/2014). We used harmonised data from the
Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS), a recent
genome-wide association study (GWAS) conducted by the Barrett’s and Esophageal Adenocar-
cinoma Consortium (BEACON).[23] Included in the present analysis were all individuals con-
tributed by investigators in the BEACON consortium to the BEAGESS. These individuals were
of white-European ancestry, representing 14 cohort and case-control studies from three conti-
nents, Australia, Europe (England, Ireland and Sweden), and North America (Canada and
United States) (S1 Text and S1 Table). Most of these studies were population-based, and have
recently been included in pooled genetic studies.[23, 24] The data were used to study the asso-
ciation between SNPs in three key genes in the oestrogen pathway and three key genes in the
oxytocin pathway. The selected genes in the oestrogen pathway were: 1) ESR1, coding for the
oestrogen receptor alpha, 2) ESR2, coding for the oestrogen receptor beta, and 3) CYP19A1,
coding for aromatase, an enzyme that catalyses the conversion of androgen to oestrogen. The
selected genes coding for the oxytocin pathway included: 1) OXTR, coding for the oxytocin
receptor, 2) OXT, coding for the oxytocin peptide, and 3) CD38, coding for the oxytocin secre-
tion regulator cyclic ADP ribose hydrolase.[20] The SNPs included in the study are presented
in S2 Table.
Genotyping
Genotyping of DNA from buffy coat or whole blood was performed using the Illumina Huma-
nOmni1-Quad platform. Annotations were based on version H of the Illumina product files
and corresponded to the Genome Reference Consortium GRCh37 release. Samples with call
rate<95% that either were an admixture of more than one DNA (n = 18), had low DNA input
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and a weak signal (n = 10), or were a noisy or poor quality sample (n = 4) were removed from
further analysis. The remaining 6448 samples, including HapMap controls (n = 68) and dupli-
cate samples (n = 67), underwent QA/QC steps as follows. We evaluated batch and plate effects
using intensity data and allelic frequency and checked for case-control associations with differ-
ent experimental factors. No important batch or plate effects or case-control associations with
experimental factors were found. We used heterozygosity, sex chromosome intensity data,
identity by descent (IBD) analysis and visualisation of B allele frequency (BAF) and log R ratio
(LRR) plots to identify samples that had one or more of misannotated sex, unexpected related-
ness, or were sample mixtures. Two sample mixtures were removed from further analysis. In
the case of misannotated sex or unexpected relatedness, if the source of the discrepancy could
be uncovered, the samples were kept; otherwise they were removed (n = 47) from further anal-
ysis. After further removing HapMap controls, duplicates and individuals with a missing call
rate>2%, 6,061 BEAGESS samples remained for final analysis: 1,508 OAC cases, 2,383 BO
cases, and 2,170 controls.
SNPs were excluded if they had a missing call rate>5%, Hardy Weinberg equilibrium p-
value among controls1e-4, a discordance among any of the duplicate pairs, a Mendelian
error, or a minor allele frequency<1%. After QA/QC a total of 802,272 SNPs remained and
were used for the initial GWAS analysis from which we selected 394 SNPs located within the
selected genes for use in the versatile gene-based test association study (VEGAS) analysis
described below.
Association analysis
Case-control analyses were conducted with an additive logistic regression model where case
status was regressed on each SNP genotype. OAC and BO were analysed separately, but since
these conditions have a shared genetic background,[24] we also analysed a combined case cate-
gory (phenotype OAC+BO) to increase power. The included covariates were sex, age and the
first four principal components eigenvectors from a principal component analysis (PCA). The
eigenvectors were included as covariates to account for population stratification due to ances-
try. P-values for each case type (OAC, BO) or OAC and BO combined were calculated for each
SNP and used as input for VEGAS. Data were also stratified by sex.
Versatile Gene-Based Test Association Study (VEGAS)
VEGAS provides a gene-based approach that considers association between a trait and all
SNPs within a specific gene or a subset of the most significant SNPs (for example the top 90%
most significant SNPs),[25] rather than each SNP marker individually, as in a conventional
GWAS. Even if the individual effect sizes at any given SNP are small, collectively, all SNPs
within a gene could still account for a substantial proportion of variation in risk. Therefore,
studies of combined risk alleles might identify candidate genes affecting disease. For some
genes, an approach considering all SNPs within each gene might be the most powerful, but for
some genes, considering only a subset of the most significant SNPs might be applicable. The
true underlying genetic architecture is seldom known in advance and both approaches might
be applicable to test. In this study, we first apply the full set of SNPs within each gene, and at a
second step we also run VEGAS when including only the top 90% SNPs within each gene to
remove non informative SNPs. Since the test including all SNPs and the one that included 90%
top SNPs were highly correlated, we did not correct for this as being a new test. By combining
the effects of all, or a subset of SNPs in a gene into a test statistic and correcting for linkage dis-
equilibrium (LD), the gene-based test can assess combined effects between SNPs that would be
missed in a GWAS. In this study, VEGAS was used to test whether there were any statistically
Oestrogen and Oxytocin Gene Variants and Barrett's
PLOS ONE | DOI:10.1371/journal.pone.0138738 September 25, 2015 4 / 13
significant effects for genes known to regulate oestrogen or oxytocin levels in OAC and BO
patients. In brief, VEGAS explore associations on a per-gene basis using the p-values from all
SNPs within a defined gene. An overlap of 10kb (upstream and downstream of the gene) for
each gene was used. VEGAS corrects for LD as well as the number of SNPs within each gene.
VEGAS takes account of LD between markers in a gene by using simulation based on the LD
structure of a set of reference individuals, or, as in this study, using a custom set of individuals
whose genotype information was available.[26] A Bonferroni corrected p-value of 0.006 was
considered statistically significant since we run 9 tests for each hormone (0.05/9 = 0.0056).
Results
Study participants
Selected characteristics of the study participants, 1508 OAC case patients, 2383 BO case
patients, and 2170 control participants, are presented in Table 1. The distributions of sex and
age were similar between these case groups and the control group.
Polymorphisms in the oestrogen pathway. When including all SNPs within each gene in
the gene-based test for the un-stratified data, none of the 3 genes tested showed significant
association in both sexes combined (Table 2). However, sex stratified analysis revealed that
genetic variants within the gene coding for the oestrogen receptor alpha (ESR1) indicated an
increased risk of OAC and BO combined in males (p = 0.0081) (Table 3). When including only
Table 1. Characteristics of oesophageal adenocarcinoma cases (OAC), Barrett’s oesophagus cases (BO), either of these (OAC+BO) and control
subjects.
BO OAC OAC+BO Controls
Number (%) Number (%) Number (%) Number (%)
Total 2383 (100) 1508 (100) 3891 (100) 2170 (100)
Men 1808 (76) 1333 (88) 3141 (81) 1704 (79)
Women 575 (24) 175 (12) 750 (19) 466 (21)
Age groups (both sexes)
<50 401 (17) 125 (8) 526 (14) 304 (14)
50–59 630 (26) 365 (24) 995 (25) 551 (26)
60–69 618 (26) 496 (33) 1114 (29) 745 (34)
70 734 (31) 522 (35) 1256 (32) 570 (26)
doi:10.1371/journal.pone.0138738.t001
Table 2. Gene-based analysis of genes known to regulate oestrogen levels and oxytocin levels and risk of Barrett’s oesophagus (BO), oesopha-
geal adenocarcinoma (OAC), and these conditions combined (OAC+BO). P-values in bold are statistically significant after correction for multiple testing.
P-value
Gene Chr1 SNPs (N) Start position (bp2) Stop position (bp2) BO OAC OAC+BO
ESR1 6 224 152011630 152424408 0.067 0.042 0.034
ESR2 14 36 64693750 64805267 0.54 0.73 0.59
CYP19A1 15 60 51500253 51630794 0.40 0.66 0.54
OXT 20 10 3052265 3053162 0.96 0.50 0.99
OXTR 3 35 8792093 8811299 0.019 0.67 0.13
CD38 4 29 15779920 15850705 0.38 0.28 0.34
1 Chromosome number
2 base pair.
doi:10.1371/journal.pone.0138738.t002
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the top 90% SNPs within each gene using the VEGAS test, variants in ESR1 were possibly asso-
ciated with an increased risk of BO and OAC combined in males and females (p = 0.0063)
(Table 4). In males, a corresponding potential association was found with BO (p = 0.0058),
which was statistically significant with BO and OAC combined (p = 0.0023) (Table 5). The
most significant SNP was rs2982684 (located in intron 4), while most other significant SNPs
were located in introns 3 and 4 (S3 Table and S4 Table). Polymorphisms in the other two stud-
ied genes in the oestrogen pathway did not reach a statistically significant level of association
with BO, OAC or OAC or BO, independent of sex stratification or inclusion of top 90% SNPs
within each gene (Tables 2 and 3; Tables 4 and 5).
Polymorphisms in the oxytocin pathway. When including all SNPs within each gene in
the gene-based test for the non-stratified data, none of the 3 genes tested in the oxytocin path-
ways showed significant association after correcting for multiple testing (Table 2). However,
the sex stratified analyses showed that genetic variants within the oxytocin receptor gene
(OXTR) were statistically borderline associated with BO in males (p = 0.0081). Moreover,
when including only the top 90% SNPs within each gene, OXTR variants were significantly
Table 3. Sex-specific gene-based analysis for genes known to regulate oestrogen levels and oxytocin levels and risk of Barrett’s oesophagus
(BO), oesophageal adenocarcinoma (OAC), and these conditions combined (OAC+BO). P-values in bold are statistically significant.
p-values females p-values males
Gene Chr1 SNPs (N) BOa OACb OAC+BOc BOd OACe OAC+BOf
ESR1 6 224 0.26 0.73 0.32 0.032 0.043 0.015
ESR2 14 36 0.69 0.37 0.90 0.33 0.59 0.37
CYP19A1 15 60 0.17 0.22 0.25 0.18 0.81 0.49
OXT 20 10 0.88 0.84 0.93 0.99 0.59 0.99
OXTR 3 35 0.83 0.90 0.78 0.0081 0.57 0.067
CD38 4 29 0.75 0.75 0.69 0.38 0.25 0.29
1 Chromosome number
a 575 cases and 466 controls
b 175 cases and 466 controls
c 751 cases and 466 controls
d 1808 cases and 1703 controls
e 1333 cases and 1704 controls, and
f 3141 cases and 1702 controls.
doi:10.1371/journal.pone.0138738.t003
Table 4. Gene-based analysis of top 90% single nucleotide polymorphisms (SNPs) in genes known to regulate oestrogen levels and oxytocin lev-
els and risk of Barrett’s oesophagus (BO), oesophageal adenocarcinoma (OAC), and these conditions combined (OAC+BO). P-values in bold are
statistically significant after correction for multiple testing.
Gene Chr1 SNPs (N) Start position (bp2) Stop position (bp2) BO 90% OAC 90% OAC+BO 90%
ESR1 6 224 152011630 152424408 0.015 0.0075 0.0063
ESR2 14 36 64693750 64805267 0.40 0.58 0.43
CYP19A1 15 60 51500253 51630794 0.24 0.45 0.35
OXT 20 10 3052265 3053162 0.96 0.50 0.99
OXTR 3 35 8792093 8811299 0.0035 0.41 0.037
CD38 4 29 15779920 15850705 0.26 0.17 0.22
1 Chromosome number
2 base pair.
doi:10.1371/journal.pone.0138738.t004
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associated to BO in both sexes combined (p = 0.0035) and in males separately (p = 0.0012)
(Tables 4 and 5). The most significant OXTR SNP was rs237902 (S5 Table). Polymorphisms in
the other two studied genes in the oxytocin pathway did not reach a statistically significant
level of association with BO, OAC or OAC or BO, independent of sex stratification or inclusion
of top 90% SNPs within each gene (Tables 2 and 3; Tables 4 and 5).
Discussion
This study demonstrated possible associations between SNPs in ESR1 and risk of BO and
OAC, and SNPs in OXTR and risk of BO. The other four genes tested, i.e. ESR2 and CYP19A1
in the oestrogen pathway and OXT and CD38 in the oxytocin pathway, did not show any statis-
tically significant association with OAC or BO.
Strengths of this study include the population-based design of the included studies, the
extensive data on genetic variants through the assessment of SNPs of relevant genes, and a
sample size that exceeds that in most previous studies concerned with BO and OAC. Yet, the
low number of female cases of OAC and BO makes it difficult to assess potential associations
in females only or to ascertain any potential differences in associations between men and
women. Chance findings from multiple testing is a threat to many genetic studies, but our
strictly defined hypotheses and the selection of analysis of only three key genes for each
hypothesis counteract such errors. Moreover, all results were corrected for multiple testing in
the statistical analyses. We used Bonferroni correction for the number of genes tested for each
hormone, which is an established method in this respect, and such approach does not need the
same low p-value as for a GWAS that needs to correct for 1M tests. Nevertheless, chance can-
not be dismissed as a potential explanation for the positive associations identified. Limited sta-
tistical power might be the reason for the lack of statistically significant associations among
females. A fraction of variance for each gene will remain unexplained, to which rare variants
may contribute. To discover rare variants and test them for association with a phenotype, a fol-
low up study could re-sequence a small initial sample size and then genotype the discovered
variants in a larger sample set. Finally, the study was based on individuals of white-European
ancestry, and the results might not be generalizable to other populations.
Table 5. Sex-specific gene-based analysis of top 90% single nucleotide polymorphisms (SNPs) in genes known to regulate oestrogen levels and
oxytocin levels and risk of Barrett’s oesophagus (BO), oesophageal adenocarcinoma (OAC), and these conditions combined (OAC+BO). P-values
in bold are statistically significant after correction for multiple testing.
p-values females p-values males
Gene Chr1 SNPs (N) BOa OACb OAC+BOc BOd OACe OAC+BOf
ESR1 6 224 0.082 0.37 0.11 0.0058 0.0087 0.0023
ESR2 14 36 0.56 0.23 0.82 0.21 0.43 0.23
CYP19A1 15 60 0.075 0.11 0.12 0.086 0.62 0.31
OXT 20 10 0.88 0.84 0.93 0.99 0.59 0.99
OXTR 3 35 0.59 0.69 0.52 0.0012 0.30 0.017
CD38 4 29 0.62 0.60 0.54 0.24 0.15 0.19
1 Chromosome number
a 575 cases and 466 controls
b 175 cases and 466 controls
c 751 cases and 466 controls
d 1808 cases and 1703 controls
e 1333 cases and 1704 controls, and
f 3141 cases and 1702 controls.
doi:10.1371/journal.pone.0138738.t005
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Gene-based tests for association are increasingly being seen as useful complements to
GWAS.[25] A gene-based approach considers association between a trait and all markers, or a
subset of markers, within a specific gene rather than each marker individually, as in a GWAS.
VEGAS assigns SNPs to each of 17,787 autosomal genes according to positions on the UCSC
Genome Browser hg19 assembly. To capture regulatory regions and SNPs in LD, we defined
gene boundaries as 10 kb. Depending on the underlying genetic architecture, gene-based
approaches can be more powerful than traditional individual SNP-based GWAS. For example,
if a gene contains more than one causative variant, several SNPs within that gene might show
marginal effects that are often indistinguishable from random noise in the GWAS results.
However, under some genetic architecture, a more powerful gene based method may be to con-
sider only the top most significant SNPs in a gene rather than the full set of SNPs. In this study,
we applied both these methods and confirmed a significant effect for ESR1 and OXTR when
including only the top 90% SNPs for each gene.
There are, to the best of our knowledge, no previous genetic studies that have addressed the
hypotheses tested in the present study. The biological effects of oestrogen are mediated by two
distinct oestrogen receptors, alpha and beta, and these exist in both sexes.[27] These receptors
often exert opposite effects on cellular processes that differentially influence the development
and the progression of cancer.[28] The oestrogen receptor alpha, of particular relevance in this
study, is associated with aberrant proliferation, inflammation and cancer development.[28]
The finding of an association between SNPs in the gene coding for the oestrogen receptor
alpha and an association to BO is therefore interesting. This finding suggests the possibility
that a functioning oestrogen pathway might act against OAC development, and therefore pos-
sibly be involved in explaining the lower incidence of this tumour in females. There were, how-
ever, a too limited number of female cases to assess potential differences in associations
between the sexes. Nevertheless, although oestrogen levels are lower in men than women, the
results indicate that the oestrogen pathway might be involved in the aetiology of malignant
progression also in males. Previous research has found a role for genetic variations in the ESR1
gene in determining post-menopausal plasma oestrogen levels in women.[10]
The finding of an increased risk of BO with variants of the OXTR is in line with the study
hypothesis. The oxytocin receptor binds to G proteins which enables oxytocin to activate mul-
tiple responses in the cell. The oxytocin system, i.e. oxytocin and the oxytocin receptor, can
influence the growth modulation of various neoplastic cells by stimulating or inhibiting cell
proliferation, depending on the characteristics and conditions of the cell. Oxytocin can inhibit
proliferation of neoplastic cells of other epithelial origin, e.g. in the ovary,[29] endometrium,
[30] prostate,[31] bone[32], breast,[33] and in neuroblastoma and glial tumours.[34] Oxytocin
can increase the intracellular concentration of cAMP resulting in decreased proliferation, a
mechanism that might be relevant for the association with BO in the present study, but further
research is needed. It is also not proven that the investigated SNPs in the oxytocin pathway
actually affect the serum levels or activity of this hormone, although previous research indicates
that such gene variants can influence oxytocin activity in humans,[20–22] which lends some
support for this genetic approach to assess levels of oxytocin as exposure.
Regarding single SNP-associations it seems likely that the association from the gene-based
analysis of ESR1 and risk of OAC or BO in men is mainly due to the most significant SNP,
rs2982684, located in intron 4, together with other SNPs spanning introns 3 and 4. Intriguingly
in this context is that several previous studies have reported associations between SNPs in
intron 4 of ESR1 and oestrogen-dependent traits,[35–39] including breast cancer risk.[36] The
most significant OXTR SNP in the present study, rs237902 is located in exon 3 and has previ-
ously been associated with behavioural phenotypes,[40, 41] as well as susceptibility to preterm
birth.[42] However, the functional relevance of this SNP remains to be clarified.
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The results of the present study require confirmation in future studies based on very large
sample sizes. In the absence of an at least equally large sample population, we tried to replicate
our positive findings in an independent cohort from the United Kingdom, including 851 BO
cases and 977 OAC cases (47% of the total case number of the present study), and 2785 control
subjects from the 1958 British Birth Cohort who were genotyped on a custom version of the
Illumina Human1.2M-Duo array.[43] This array comprised less SNPs in each of the candidate
genes compared to the Illumina HumanOmni-1-Quad array used for the BEAGESS sample.
We analysed the replication dataset in a similar fashion as the main study, but none of the asso-
ciations between SNPs in ESR1 and OXTR in relation to risk to BO or OAC replicated. The
lack of replication might be due to that the positive findings from the main dataset were a result
of chance errors. However, the lack of replication was not entirely unexpected due to the lim-
ited size of the replication sample. Thus, replication in a larger sample is needed.
In conclusion, this large-scale study of polymorphisms in genes coding for the oestrogen
and oxytocin pathways provides some evidence that variants in genes coding the oestrogen
receptor alpha and the oxygen receptor might be associated with the risk of BO, OAC, and BO
or OAC. These findings indicate a possible hormonal influence in the sex difference in inci-
dence of BO and OAC, but the results need to be cautiously interpreted and require confirma-
tion in future large-scale studies.
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